Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3537955 | 0.90 | ALDH1A1 (0.66) | PKMALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL4028241 | 0.87 | PKM (0.55) | PKMALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL3540197 | 0.83 | ALDH1A1 (0.56) | PKMALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL4032573 | 0.83 | PKM (0.51) | PKMALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL4033939 | 0.78 | ALDH1A1 (0.64) | PKMALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL5347059 | 0.73 | ALDH1A1 (0.97) | PKMALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL2360974 | 0.73 | ALDH1A1 (0.84) | PKMALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL4028245 | 0.72 | PKM (0.51) | PKMALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL28137833 | 0.71 | ALDH1A1 (1.00) | PKMALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL2061369 | 0.69 | PKM (0.76) | PKMALDH1A1POLBKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1244648-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORP (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20070060591-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-7022717-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED, INC. (CA) | 2006-04-04 | — | — | US | disclosed |
| US-20060069129-A1 | Chemokine receptor binding heterocyclic compounds | BRIDGER GARY J | 2006-03-30 | — | — | US | disclosed |
| US-20040102428-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED CORPORATION (CA) | 2004-05-27 | — | — | US | disclosed |
| US-6667320-B2 | For therapy of infalmmation; asthma, cancer, arthritis, multiple sclerosis; prophylaxis of infection of target cells by a human immunodeficiency virus (HIV) | ANORMED (CA) | 2003-12-23 | — | — | US | disclosed |
| US-20020077339-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED CORPORATION (CA) | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060591-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | PKM 1780/4885ALDH1A1 3141/4885POLB 1285/4885 |
| US-20040102428-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | PKM 1780/4885ALDH1A1 3141/4885POLB 1285/4885 |
| US-20020077339-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | PKM 1780/4885ALDH1A1 3141/4885POLB 1285/4885 |
| US-20060069129-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | PKM 1780/4885ALDH1A1 3141/4885POLB 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.